copenlu/druid huggingface dataset:
Claim: “Would you take a vaccine with a 33% death rate to feel safe from a virus with a .06% death rate?” (Facebook users, 2020-08-15)
Evidence (2023-02-10): Assoumou: The vaccines are safe, and remarkably effective. But what precautions to take will decide on a lot of factors. For example, where you live. Are you in a place with high vaccination coverage, like Massachusetts, or a southern state with low vaccination coverage and high case rate. It also depends on what activity you are engaging in. Outside not in a crowd, that’s safe. You don’t need a mask, but inside in a crowd where you don’t know who is vaccinated or unvaccinated, then you may still want to follow public health measures. If you have children less than 12, like I do, then you also need to be a little more cautious. In addition, if you have a compromised immune system, then you also need to take some precautions. If you happen to be in a place with high vaccination coverage and a lower case rate, then it might depend on your level of comfort for risk.
Claim: “Would you take a vaccine with a 33% death rate to feel safe from a virus with a .06% death rate?” (Facebook users, 2020-08-15)
Evidence (2018-09-11): Of course, with or without recycling, a pattern like those seen in 1957 or 1968 would result in the elderly having a higher absolute risk of death. If the metric used to measure effectiveness of vaccination were "numbers of deaths prevented," then perhaps the elderly should be given priority—assuming they can produce an adequate antibody response to the pandemic vaccine. But if the concern is to minimize the years-of-life-lost, then the vaccine may be better used in young and middle-aged adults. This point was illustrated in a paper that sought to determine vaccination priorities by age and risk status; when basing priority on "returns due to vaccination," an endpoint that is heavily influenced by years of life lost, the young and middle aged rose to the top of the priority list (Meltzer et al., 1999). Other authors have proposed that children be given priority to receive pandemic vaccine (Stuart-Harris, 1970; Longini et al., 1978; Reichert et al., 2001) and antivirals (Longini et al., 2004) in order to reduce transmission in the community and thereby indirectly reduce influenza impact among the elderly.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2020-12-18): Accurate: It is accurate to claim that the U.S. Food and Drug Administration (FDA) advisory committee provided a positive statement about the COVID-19 vaccine developed by the biotech Moderna Lack of context : The claims do not mention that FDA approval is not finalized yet. They also overlook the fact that Emergency Use Authorization of a vaccine is based on different and more tolerant standards than a standard approval.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2024-01-01): FDA advisory panel backs Moderna’s Covid-19 vaccine was Dkr4188 now Dkr1999 for your first year, equivalent to Dkr166.58 per month. Make up your own mind. Build robust opinions with the FT’s trusted journalism. Take this offer before 24 October.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2020-12-17): WASHINGTON (AP) — A government advisory panel endorsed a second COVID-19 vaccine Thursday, paving the way for the shot to be added to the U.S. vaccination campaign. Watch the meeting in the player above. The Food and Drug Administration is expected to follow the recommendation for the vaccine from Moderna and the National Institutes of Health. The FDA advisers, in a 20-0 vote, agreed the benefits of the vaccine outweighed the risks for those 18 years old and up. The FDA’s green light for emergency use is expected quickly. Moderna would then begin shipping millions of doses, earmarked for health workers and nursing home residents, to boost the largest vaccination effort in U.S. history. The campaign kicked off earlier this week with the first vaccine OK’d in the U.S., developed by Pfizer and BioNTech. Moderna’s shot showed similarly strong protection, providing 94% protection against COVID-19 in the company’s ongoing study of 30,000 people. WATCH: HHS holds kickoff event for COVID-19 vaccine After seven hours of debate over technical details of the company’s study and follow-up plans, nearly all panelists backed making the vaccine available to help fight the pandemic. One panel member abstained.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2021-10-14): - On Thursday the FDA's expert panel voted in favor of booster shots of Moderna's COVID-19 vaccine. [...] A panel of independent experts convened by the Food and Drug Administration voted unanimously Thursday in favor of a Moderna booster shot for certain people who got their shot at least six months ago. The group supported offering an extra dose to adults 65 years and older, as well as younger adults who are at high risk of severe COVID-19. The recommendation, backed by a 19-0 vote by the committee, clears the way for the FDA to authorize a booster of Moderna's vaccine for more people. The FDA typically follows the recommendations of its advisory panel, but it is not required to do so.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2021-10-14): The FDA panel wrestled with whether Moderna presented enough evidence backing its low-dose booster. [...] Moderna’s COVID-19 vaccine does a significantly better job of preventing COVID-19 hospitalizations compared with Pfizer’s shot. [...] The FDA advisors found that data reassuring because the Moderna vaccine is similar to the Pfizer one.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2022-02-04): A federal advisory panel voted unanimously Friday to continue to endorse Moderna's Covid-19 vaccine for adults, now that U.S. regulators have given the shots their full approval. The decision has little practical effect. Tens of millions of Americans have already gotten Moderna shots, following its emergency authorization by the Food and Drug Administration more than a year ago. [...] The panel heard summaries of medical studies that showed the vaccine is working against the coronavirus and there is no evidence of new safety concerns.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2020-12-17): Leave a comment 0comments Share Copy URL https://www.pbs.org/newshour/show/news-wrap-fda-panel-backs-modernas-covid-19-vaccine-for-emergency-use Email Facebook Twitter LinkedIn Pinterest Tumblr Share on Facebook Share on Twitter Transcript Audio In our news wrap Thursday, a second COVID-19 vaccine moves closer to emergency authorization, President-elect Biden rounds out his environmental team, Vladimir Putin denies ordering opposition leader's poisoning, more than 340 boys kidnapped in Nigeria are freed, the family that owns Purdue Pharma admits Oxycontin has helped fuel opioid addictions, and Google faces another major antitrust lawsuit. Read the Full Transcript Notice: Transcripts are machine and human generated and lightly edited for accuracy. They may contain errors. Judy Woodruff: In the day's other news: A panel of experts endorsed a second COVID-19 vaccine for emergency use. They recommended the Moderna vaccine to the U.S. Food and Drug Administration, as deaths nationwide passed 310,000.In California, hospital staffers now have beds in hallways and ambulances lined up, and it's getting worse, with 100,000 new infections there in two days. Mohamed Fayed: Nurses and physicians and all the health care workers are really working so hard through this, hours and hours and hours and hours per day nonstop. People are taking two shifts just to get through this.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2021-10-14): FDA Panel Backs Moderna Booster for Older, High-Risk People - Recommendations echo U.S. guidance on Pfizer vaccine booster - J&J booster shot will be weighed by expert panel on Friday [...] Booster shots of Moderna Inc.’s Covid-19 vaccine should be given to older people and those at high risk of the disease, advisers to U.S. regulators said. Additional doses of the two-shot messenger RNA vaccine should be offered to people 65 and older, along with adults 18 and older who are at high risk for medical or occupational reasons, the Food and Drug Administration’s vaccine advisory panel said Thursday in a unanimous, 19-0 vote.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2024-08-30): FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose [...] The FDA approved a second COVID-19 vaccine. The vaccine has been known as the Moderna COVID-19 Vaccine; the approved vaccine will be marketed as Spikevax for the prevention of COVID-19 in individuals 18 years of age and older. [...] Following today’s positive advisory committee meeting outcome regarding the Moderna COVID-19 vaccine, the FDA has informed the sponsor that it will rapidly work toward finalization and issuance of an emergency use authorization.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2021-10-26): By — Lauran Neergaard, Associated Press Lauran Neergaard, Associated Press By — Matthew Perrone, Associated Press Matthew Perrone, Associated Press Leave your feedback Share Copy URL https://www.pbs.org/newshour/health/fda-panel-backs-pfizers-low-dose-covid-19-vaccine-for-kids Email Facebook Twitter LinkedIn Pinterest Tumblr Share on Facebook Share on Twitter FDA panel backs Pfizer’s low-dose COVID-19 vaccine for kids Health Oct 26, 2021 5:17 PM EDT WASHINGTON (AP) — The U.S. moved a step closer to expanding COVID-19 vaccinations for millions more children as a panel of government advisers on Tuesday endorsed kid-size doses of Pfizer’s shots for 5- to 11-year-olds. A Food and Drug Administration advisory panel voted unanimously, with one abstention, that the vaccine’s benefits in preventing COVID-19 in that age group outweigh any potential risks — including a heart-related side effect that’s been very rare in teens and young adults despite their use of a much higher shot dose.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2022-06-15): FDA advisers back Moderna’s COVID-19 vaccine for older kids [...] Moderna’s COVID-19 vaccine has long been available for adults in the U.S. and elsewhere and more than three dozen countries offer it to children, too. If the FDA authorizes Moderna’s vaccine for teens and younger children, the Centers for Disease Control and Prevention will next decide whether to recommend the shots. [...] The FDA analysis concluded that two doses of Moderna are effective in preventing symptomatic COVID-19 illness in teens and younger kids, with the levels of virus-fighting antibodies comparable to those developed in young adults.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2020-12-30): On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Moderna COVID-19 (mRNA-1273) vaccine (ModernaTX, Inc; Cambridge, Massachusetts), a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) (1). This vaccine is the second COVID-19 vaccine authorized under an EUA for the prevention of COVID-19 in the United States (2). Vaccination with the Moderna COVID-19 vaccine consists of 2 doses (100 μg, 0.5 mL each) administered intramuscularly, 1 month (4 weeks) apart. On December 19, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation* for use of the Moderna COVID-19 vaccine in persons aged ≥18 years for the prevention of COVID-19. To guide its deliberations regarding the vaccine, ACIP employed the Evidence to Recommendation (EtR) Framework,† using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.§ Use of all COVID-19 vaccines authorized under an EUA, including the Moderna COVID-19 vaccine, should be implemented in conjunction with ACIP’s interim recommendations for allocating initial supplies of COVID-19 vaccines (3).
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2022-06-16): America's FDA panel backs Moderna and Pfizer COVID-19 vaccines for children under five. Here's what that means [...] The decision of US regulators is likely to be watched closely by Australian health officials, who are already evaluating an application from Moderna to extend its COVID-19 vaccine to children as young as six months. [...] Data submitted to the FDA suggested Pfizer's vaccine was around 80 per cent effective in preventing symptomatic COVID-19 infections, however, that was based on just 10 COVID-19 cases.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2022-06-15): FDA advisers back Moderna's COVID-19 vaccine for older kids [...] Moderna's COVID-19 vaccine has long been available for adults in the U.S. and elsewhere and more than three dozen countries offer it to older children, too. If the FDA authorizes Moderna's vaccine for teens and younger children, the Centers for Disease Control and Prevention will next decide whether to formally recommend the shots. [...] The FDA analysis concluded that two doses of Moderna are effective in preventing symptomatic COVID-19 illness in teens and younger kids, with the levels of virus-fighting antibodies comparable to those developed in young adults.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2024-01-01): US FDA panel backs Novavax Covid jab with hopes of persuading sceptics was Dkr4188 now Dkr1999 for your first year, equivalent to Dkr166.58 per month. Make up your own mind. Build robust opinions with the FT’s trusted journalism. Take this offer before 24 October.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2024-09-30): - mRNA vaccines - Moderna COVID-19 Vaccine (2024–2025 Formula) is authorized for children ages 6 months–11 years; SPIKEVAX is the licensed Moderna product for people ages 12 years and older. These vaccines are hereafter referred to as 2024–2025 Moderna COVID-19 Vaccine. [...] On a case-by-case basis, providers caring for these patients may administer Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines outside of the FDA and CDC dosing intervals when, based on their clinical judgment, the benefits of vaccination are deemed to outweigh the potential and unknown risks for the recipient who is immunocompromised. [...] For licensed COVID-19 vaccines (Moderna and Pfizer-BioNTech in people ages 12 years and older), healthcare providers are strongly encouraged to report to VAERS:
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2024-01-08): FDA authorizes Pfizer and Moderna COVID vaccines for children under 5 FDA panel backs Moderna’s COVID-19 vaccine for youngest kids [...] FDA postpones meeting on Pfizer COVID shot for kids under 5
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2024-09-30): - FDA Authorizes New COVID-19 Vaccine [...] June 23, 2023 — Moderna has applied for FDA approval of a new COVID-19 vaccine targeting the predominant strain of the virus called XBB.1.5. The company said it is prepared to roll out the shot this fall. [...] - FDA Panel Backs Shift Toward One-Dose COVID Shot
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2022-02-04): Expert panel backs Moderna shots after full US approval New York — The Centers for Disease Control and Prevention on Friday continued its endorsement of Moderna’s COVID-19 vaccine for adults, now that U.S. regulators have given the shots their full approval. [...] The panel heard summaries of medical studies that showed the vaccine is working against the coronavirus and there is no evidence of new safety concerns. It voted unanimously to continue to endorse the shots, and the agency’s director later signed off on the recommendation.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2024-08-22): FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants - For Immediate Release: Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2. The mRNA COVID-19 vaccines have been updated with this formula to more closely target currently circulating variants and provide better protection against serious consequences of COVID-19, including hospitalization and death. Today’s actions relate to updated mRNA COVID-19 vaccines manufactured by ModernaTX Inc. and Pfizer Inc. [...] For today’s approvals and authorizations of the mRNA COVID-19 vaccines, the FDA assessed manufacturing and nonclinical data to support the change to include the 2024-2025 formula in the mRNA COVID-19 vaccines. The updated mRNA vaccines are manufactured using a similar process as previous formulas of these vaccines. The mRNA COVID-19 vaccines have been administered to hundreds of millions of people in the U.S., and the benefits of these vaccines continue to outweigh their risks.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2021-04-24): An FDA advisory panel endorses the first COVID-19 vaccine. The application for the Pfizer and BioNTech’s vaccine is heard in a public, day-long meeting; voting 17-4, with 1 abstention, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) decides the benefits of the vaccine outweigh the risks for those 16 and older. [...] December 17 — FDA Panel Backs Moderna COVID-19 Vaccine [...] December 18 — FDA Signs Off on EUA for Moderna's COVID-19 Vaccine
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2024-08-23): Moderna COVID-19 Vaccine (2024-2025 Formula) Authorized For Individuals 6 Months through 11 Years of Age On August 22, 2024, the Food and Drug Administration amended the emergency use authorization (EUA) of Moderna COVID-19 Vaccine to include the 2024-2025 formula. The Moderna COVID-19 Vaccine (2024-2025 Formula) includes a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2. The Moderna COVID-19 Vaccine (2024-2025 Formula) is authorized for all doses administered to individuals 6 months through 11 years of age to prevent COVID-19. Moderna COVID-19 Vaccine (2024-2025 Formula) is authorized for use as follows:
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2021-09-23): Dr. Sara Oliver, a CDC scientist, stressed at Thursday's advisory meeting that because the federal government has purchased all of the COVID-19 vaccines on an emergency basis for the pandemic, including the Pfizer vaccine, vaccine providers are required to follow the recommendations of the CDC and the FDA. [...] U.S. regulators will rule on booster guidance for those who have gotten the Moderna or Johnson & Johnson vaccine at a later date, The Associated Press reported. Moderna's two-shot vaccine and Johnson & Johnson's one-shot vaccine are currently offered under an emergency use authorization, pending formal FDA approval. Like the FDA, the CDC panel's decision breaks with the Biden administration's sweeping booster strategy to offer an extra dose to most age groups as early as this week in an effort to protect Americans against the highly contagious delta variant.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2021-10-14): FDA panel backs Moderna COVID booster shot for high-risk Americans, clearing the way for a 3rd jab A key federal advisory committee voted unanimously Thursday to recommend emergency authorization of a booster shot for older and more vulnerable recipients of Moderna’s COVID-19 vaccine, a sign that millions of Americans who received their second Moderna dose at least six months ago will likely be cleared for a third jab as soon as next weekend. [...] "Some real-world effectiveness studies have suggested declining efficacy of Moderna COVID-19 vaccine over time against symptomatic infection or against the Delta variant, while others have not," the FDA scientists said in the briefing document.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2022-06-15): US FDA panel backs first Covid-19 jabs for children under five [...] The Food and Drug Administration’s vaccine advisers gave a thumbs-up to vaccines from Moderna and Pfizer for the littlest kids. [...] The same FDA panel on Tuesday backed Moderna’s half-sized shots for ages 6 to 11 and full-sized doses for teens. If authorized by the FDA, it would be the second option for those age groups. Currently the Pfizer vaccine is their only choice.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2021-10-15): US health advisers said on Thursday that some Americans who received Moderna’s Covid vaccine should get a half-dose booster to bolster protection against the virus. The panel of advisers to the Food and Drug Administration voted unanimously to recommend a booster shot for seniors, adults with other health problems, jobs or living situations that put them at increased risk for Covid. [...] "It’s important to remember that the vaccines still provide strong protection against serious outcomes" such as hospitalization and death from Covid, said FDA vaccine chief Peter Marks.
Claim: 'FDA panel backs Moderna’s COVID-19 vaccine' (CNET editors, 2020-12-18)
Evidence (2022-06-14): The US Food and Drug Administration's (FDA) vaccine advisory panel today unanimously recommended granting emergency use authorization (EUA) for Moderna's COVID-19 vaccine for ages 6-17 years. [...] In today's presentations to the FDA panel Moderna's Jacqueline Miller, MD, therapeutic area head for infectious diseases, reported that more than 8000 children aged 6-17 have been included in the clinical trials for the vaccine. [...] Cite this: FDA Panel Unanimously Backs Moderna COVID Vaccine for Ages 6-17 - Medscape - Jun 14, 2022.
Claim: If masks were effective and necessary, non-mask wearers should be dead by now (Facebook Users, 2020-07-30)
Evidence (2020-07-30): Factually inaccurate: The claim states that people not wearing masks should be dead. However, this is not consistent with the epidemiological data to date indicating that only 0.5% to 0.7% of SARS-CoV-2 infections result in death, based on the infection fatality ratio. Flawed reasoning: The claim implies that masks are ineffective or useless against COVID-19, otherwise non-mask wearers should be dead. However, protective equipment can be recommended or necessary even against diseases that are not systematically deadly. The claim also forgets to consider that the use of masks reduces the propagation of the virus among the population and thus indirectly limits the risk of exposure of non-mask wearers.